Top 10 advances in psoriasis research for physicians

Psoriasis, a chronic inflammatory disease of the immune system that primarily affects skin and joints, affects nearly 7.5 million people in the United States.

According to the American Academy of Dermatology, the cost of psoriasis-associated treatment "was estimated to be between $51.7 billion and $63.2 billion," in 2013.

Marking Psoriasis Awareness Month, Healio Internal Medicine presents the 10 most popular stories on psoriasis thus far in 2016.

Psoriasis associated with type 2 diabetes, obesity in twin study

Psoriasis had a strong association with type 2 diabetes and obesity in a nationwide study of Danish twins, indicating a common genetic etiology between psoriasis and obesity, according to study results recently published in JAMA Dermatology. Read more.

Taltz , Consentyx show efficacy in year-long treatment of psoriasis

Research from two separate studies showing year-long efficacy results of for Taltz and Cosentyx treatments for psoriasis were presented at a late-breaking research forum at the American Academy of Dermatology Annual Meeting. Read more.

No significant difference found between Otezla , methotrexate in treating psoriasis

There were no statistically significant differences found in efficacy between Otezla and methotrexate for moderate-to-severe psoriasis, according to recently published study results. Read more.

Patients with psoriasis treated with Taltz reported improvements in work productivity

Patients with moderate-to-severe psoriasis who were treated with Taltz reported improvement in work productivity between 12 and 60 weeks compared with patients treated with placebo and, in some incidences, those treated with Enbrel, according to study results. Read more.

Psoriasis patients treated by lasers show no indication of koebnerization

Patients with plaque psoriasis who underwent laser treatment did not show evidence of subsequent koebnerization, according to recent research. Read more.

Otezla effective in patients with palmoplantar psoriasis

Patients in this study with moderate-to-severe palmoplantar psoriasis showed clinical improvement at 16 weeks after treatment with Otezla compared with placebo, according to recent data. Read more.

Patients with psoriasis effectively switch from Remicade to infliximab biosimilar

Patients with psoriasis being treated with Remicade had no significant change in clinical response and experienced minor adverse events when switching to an infliximab biosimilar, according to recently published study results. Read more.

Ixekizumab shows continued efficacy for 60-week treatment of psoriasis

In a video perspective from the American Academy of Dermatology Annual Meeting, Andrew Blauvelt, MD, MBA, discusses his research showing that Taltz had continued efficacy in treating patients with psoriasis through week 60. Watch here.

Stelara superior to TNF-α inhibitors in treating psoriasis at 6, 12 months

Stelara was significantly more effective in treating patients with psoriasis compared with three tumor necrosis factor-alpha inhibitors at 6 months and 12 months, according to recently published study results. Read more.

Complete skin clearance represents meaningful endpoint for patients with psoriasis

Complete skin clearance in patients with psoriasis was a clinically meaningful endpoint and outcome, with no impairment on health-related quality of life, according to recently published study results. Read more.